Observational studyFrontiers in endocrinology2026
The correlation between the atherogenic index of plasma and aortic valve calcification in the general population: a retrospective observational cohort study.
Observational study in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to explore the correlation between atherogenic index of plasma (AIP) and the risk of aortic valve calcification (AVC). Method: This single-center retrospective cohort study included 1,752 participants from the First Affiliated Hospital of Xinjiang Medical University, from May 27, 2023, to Ju\ly 27, 2025. Participants were divided into two groups based on AVC at follow-up: non-AVC group (n = 1,463) and AVC group (n = 289). Multivariate logistic regression, subgroup and sensitivity analyses, and receiver operating characteristic (ROC) curve analysis evaluated the evaluate the correlation between AIP and AVC. Results: Multivariable logistic regression analysis showed that each 1-unit increase in AIP was associated with a 146.0% higher risk of AVC (OR = 2.460, 95% CI 1.525-3.969). When participants were grouped by AIP quartiles, compared with the lowest quartile (Q1), the risk of AVC in the Q2, Q3, and Q4 groups was 1.623-fold (95% CI 1.080-2.439, P = 0.020), 2.405-fold (95% CI 1.622-3.567, P < 0.001), and 2.319-fold (95% CI 1.564-3.439, P < 0.001), respectively. Subgroup analysis indicated that higher AIP levels remained significantly associated with an increased risk of AVC across most subgroups (all P < 0.05). Sensitivity analysis, after excluding participants with eGFR < 60 mL/min/1.73 m², showed that each 1-unit increase in AIP was associated with a 143.2% higher risk of AVC. In that analysis, the AVC risk in Q2, Q3, and Q4 remained 2.086-fold, 2.928-fold, and 3.172-fold that of Q1, respectively. When grouped by the median AIP, the high-AIP group had a 1.996-fold higher risk; when grouped by the mean AIP, the risk was 2.067-fold higher. Using AIP tertiles, the Q2 and Q3 groups had 2.151-fold and 2.807-fold higher risks, respectively. ROC curve analysis indicated that AIP had moderate diagnostic value for AVC risk (AUC = 0.760, 95% CI 0.732-0.789). In contrast, the AUCs for triglycerides (0.594) and total cholesterol (0.538) were significantly lower than that of AIP (DeLong test, both P < 0.05). Conclusion: Higher levels of AIP are significantly associated with an increased risk of AVC, indicating that AIP holds important clinical value as an associative biomarker for AVC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.